JPRN-UMIN000024985已完成2 期
Discontinuation study of nilotinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter stop study in Japan adult leukemia study group - JALSG-D-STOP216
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 51
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 16years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. CML patients in CP, who had an experience of treatment with TKI other than dasatinib or interferon-a for more than 4 weeks 2. CML patients in CP, who have been treated with dasatinib with a daily dose less than 50mg excepting transient dose reduction due to the adverse events 3. CML patients in CP, who had an experience of allogeneic hematopoietic stem cell transplantation 4. CML patients in CP with an episode of disease progression to accelerated or blastic phase 5. CML patients in CP with an episode of loss of CMR despite the continuous treatment with dasatinib 6. CML patients in CP with poor adherence to dasatinib 7.CML patients in CP, who don't accept retreatment with dasatinib after losing TFR 8. CML patients in CP with other inappropriate conditions for the trial
研究者
相似试验
已完成
2 期
Discontinuation study of nilotinib in patients with chronic myeloid leukemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter stop study in Japan adult leukemia study groupchronic myeloid leukemiaJPRN-UMIN000024984Japan Adult Leukemia Study Group51
进行中（未招募）
1 期
Treatment for patients whith graft-versus-host disease after bone marrow transplantation.Chronic graft-versus-host disease .MedDRA version: 14.1Level: LLTClassification code 10008907Term: Chronic GVH diseaseSystem Organ Class: 100000004870EUCTR2012-000770-36-BECHU-ULg5
招募中
2 期
Clinical study evaluating efficacy of Nilotinib in CML patientsChronic myelogenous leukemiaJPRN-UMIN000002579ara Hospital Kinki University School Of Medicine20
进行中（未招募）
1 期
A Phase II Trial of Nilotinib in the Treatment of Patients with c-KIT Mutated Advanced Acral and Mucosal Melanoma (NICAM) - Nilotinib in the Treatment of c-KIT Mutated Melanoma (NICAM)c-KIT mutated advanced acral or mucosal melanomaMedDRA version: 10 Level: LLT Classification code 10025654 Term: Malignant melanoma of sites other than skinMedDRA version: 10 Level: LLT Classification code 10000583 Term: Acral lentiginous melanomaEUCTR2009-012945-49-GBRoyal Marsden Hosptial Foundation Trust29
已完成
2 期
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicenter Stop Imatinib in Japan adult leukemia study group studyChronic Myeloid Leukemia Chronic phaseJPRN-UMIN000011971Japan Adult Leukemia Study Group62